In fact, large series of human studies have further provided evidence on the therapeutic potential of targeting the CCL2‐CCR2 (C‐C motif chemokine receptor 2) pathway in human atherosclerotic disease (Georgakis et al, 2022), which could also be relevant to minimize the risk of secondary cardiovascular complications after stroke. The gene discussed is CCL2; the disease is Stroke.